AXS-12 (reboxetine) is a highly selective and potent norepinephrine reuptake inhibitor being developed for the treatment of narcolepsy. It is thought to modulate noradrenergic activity to promote wakefulness, maintain muscle tone and enhance cognition.
Reboxetine has an extensive safety record in Europe and in over 40 countries where it’s approved for the treatment of depression.
In narcolepsy, AXS-12 is supported by positive pre-clinical and Phase 2 clinical results.
AXS-12 is an investigational drug not approved by the FDA and its safety and effectiveness have not been established.
clinical and regulatory
AXS-12 has been granted U.S. Food and Drug Administration (FDA) Orphan Drug designation for the treatment of narcolepsy. The product is in phase 3 of development.